# metabolic dysfunction-associated steatohepatitis (MASH) - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: liver tissue
- Comparison or endpoint: MASH/NASH versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: f634f84e95c290ce4195eb13604b114b4c86ce8adb76238e59c436c955ac43b9
- Response HTTP status: 200
- Prompt tokens: 4024
- Completion tokens: 21825
- Reasoning tokens: 
- Total tokens: 25849
- API requests reported: 
- Elapsed seconds: 236.614
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
# Multidimensional interpretation of the MASH versus healthy liver transcriptome

## 1. Overall biological interpretation

In this MASH versus healthy liver comparison, the most prominent transcriptomic signal is a coordinated shift in hepatic myeloid cell identity. A large set of genes that define homeostatic liver-resident Kupffer cells is strongly decreased, including **TIMD4, LYVE1, MRC1, CD163, MARCO, CD5L, FOLR2, CSF1R, CD209, SIGLEC1, SPIC, CR1, P2RY13 and MS4A6E**. In parallel, **TREM2, FABP5 and CAPG** are upregulated, a combination that is characteristic of TREM2-positive lipid-associated or scar-associated macrophages in steatohepatitis.

Superimposed on this immune cell shift are several non-macrophage programs:

- an **interferon / NF-κB inflammatory module** evidenced by **CXCL10, UBD and TNFRSF12A**,
- a **cell-cycle / DNA-damage / p53 response** evidenced by **FOXM1, EME1, TP53I3 and CYCS**,
- a **mitochondrial / translational / ER stress response** evidenced by mitochondrial tRNAs, **TIMM17A, CYCS, MANF and MTRNR2L8**,
- a **one-carbon / sulfur / glutathione metabolic shift** evidenced by **CBS↓, GNMT↓ (CNPY3-GNMT), SCLY↓, MTHFD1L↑ and GGTLC1↑**.

Taken together, these results are consistent with a model in which MASH liver tissue loses homeostatic Kupffer cell identity, acquires disease-associated macrophage and inflammatory programs, and undergoes oxidative, mitochondrial and regenerative stress.

---

## 2. Core biological programs

### 2.1. Loss of resident Kupffer cells and emergence of TREM2-positive MASH-associated macrophages

- **Direction:** Resident Kupffer markers down; TREM2/lipid-associated macrophage markers up.
- **Supporting genes:**  
  - Down: **TIMD4, LYVE1, MRC1, CD163, MARCO, CD5L, FOLR2, CSF1R, CD209, SIGLEC1, SPIC, CR1, P2RY13, MS4A6E**  
  - Up: **TREM2, FABP5, CAPG**
- **Pathway reference:** No single canonical gene set captures this exact cell-state switch. The closest useful annotations are **KEGG Phagosome** for downregulated scavenger/macrophage receptors and **GO myeloid/macrophage activation** for the combined set. In the context of TREM2 biology, **Reactome TREM2 signaling** is relevant.
- **Explanation:** The simultaneous loss of many independent Kupffer-cell-defining transcripts and upregulation of TREM2/FABP5 is unlikely to be explained by a single-gene artifact. It strongly suggests that the resident macrophage compartment is depleted or loses identity, while disease-associated TREM2-positive macrophages expand.
- **Strength and limitations:** Strong, because dozens of lineage-defining markers move coherently. The major limitation is that bulk tissue cannot distinguish loss or replacement of Kupffer cells from downregulation of these genes within the same cells. Some markers, such as LYVE1, are also expressed by sinusoidal endothelium, so the signal may include endothelial changes.

### 2.2. Interferon-γ / NF-κB inflammatory and chemokine response

- **Direction:** Upregulated.
- **Supporting genes:** **CXCL10, UBD, TNFRSF12A**; related inflammatory context: **DUSP8, CAPG**
- **Pathway reference:** **Hallmark Interferon Gamma Response**, **KEGG Chemokine Signaling Pathway**, **Reactome NF-κB Signaling**.
- **Explanation:** **CXCL10** is a direct interferon-responsive chemokine that recruits CXCR3-positive T cells and inflammatory monocytes. **UBD** (FAT10) is an interferon-inducible ubiquitin-like modifier that can regulate NF-κB activity. **TNFRSF12A** encodes the TWEAK receptor, which activates NF-κB and promotes tissue injury and inflammation. These genes are functionally connected through inflammatory signaling cascades rather than by direct physical interaction.
- **Strength and limitations:** Supported by multiple independent interferon/NF-κB-related genes. The limitation is that the cellular source is not identifiable from bulk tissue, and some expected endothelial inflammatory genes, such as VCAM1, are actually downregulated, so this program is not universal across all liver cell types.

### 2.3. Hepatocyte injury, cell-cycle activation and DNA-damage response

- **Direction:** Upregulated.
- **Supporting genes:** **FOXM1, EME1, TP53I3, CYCS**; also **DYNLT1, MACROH2A2**
- **Pathway reference:** **Hallmark G2M Checkpoint**, **Reactome Homologous Recombination Repair**, **KEGG p53 Signaling Pathway**.
- **Explanation:** **FOXM1** is a regulator of G2/M progression and compensatory proliferation. **EME1** participates in DNA repair as part of the structure-specific endonuclease complex. **TP53I3** is a p53-inducible gene associated with oxidative stress and apoptosis. **CYCS**, cytochrome c, is involved in both mitochondrial electron transport and intrinsic apoptosis. Combined, these genes suggest hepatocyte or liver progenitor injury with DNA damage, p53 checkpoint activation and regenerative/proliferative pressure.
- **Strength and limitations:** Multiple independent genes point in the same direction. The main limitation is cell-type ambiguity: this program could reflect hepatocyte regeneration, ductular progenitor expansion, or proliferation of non-parenchymal cells.

### 2.4. Mitochondrial, translational and ER stress response

- **Direction:** Upregulated.
- **Supporting genes:** **CYCS, TIMM17A, MANF, MTRNR2L8, UQCRBP1** and multiple mitochondrial tRNAs: **TRNK, TRNS1, TRNC, TRNY, TRNL2**; ribosomal genes **RPL9, RPSA2**
- **Pathway reference:** **Reactome Mitochondrial Translation**, **GO Mitochondrial Gene Expression**, and **Unfolded Protein Response / ER stress** for MANF-related biology.
- **Explanation:** Mitochondrial tRNAs and import/translocase machinery are coordinately increased, along with cytochrome c and mitochondrial-derived peptide transcripts. **MANF** is an ER stress-inducible cytoprotective factor. This pattern is consistent with mitochondrial dysfunction, ER stress and compensatory mitochondrial/translational activation in MASH.
- **Strength and limitations:** The consistency of mitochondrial transcripts is notable, but many of these features are non-coding, mitochondrial or pseudogene-like, which raises concerns about technical artifacts, mitochondrial content differences, or RNA preservation effects. This program should therefore be interpreted more cautiously than the macrophage and inflammatory programs.

### 2.5. One-carbon / sulfur / glutathione metabolic reprogramming

- **Direction:** Mixed; key enzymes of sulfur and methyl-group metabolism are downregulated, while related stress-associated enzymes are upregulated.
- **Supporting genes:**  
  - Down: **CBS, SCLY, CNPY3-GNMT** (likely reflecting GNMT)  
  - Up: **MTHFD1L, GGTLC1**
- **Pathway reference:** **KEGG Cysteine and Methionine Metabolism**, **Reactome Folate Metabolism**, **KEGG One Carbon Pool by Folate**.
- **Explanation:** **CBS** encodes cystathionine β-synthase, a key enzyme in transsulfuration, glutathione synthesis and hydrogen sulfide production. Its decrease may reduce glutathione precursor availability and antioxidant capacity. **GNMT** is a major liver enzyme that regulates S-adenosylmethionine (SAM) methylation status; reduced GNMT is relevant to steatosis and liver cancer risk. **MTHFD1L** connects mitochondrial folate one-carbon metabolism, and **GGTLC1** is involved in glutathione turnover. This pattern suggests a coordinated alteration in methylation and antioxidant metabolism.
- **Strength and limitations:** Supported by multiple enzymes in connected metabolic pathways. The main limitations are that expression alone cannot prove metabolic flux; dietary methionine, folate and glutathione status are unknown; and the **CNPY3-GNMT** signal is a read-through transcript that may not exactly represent GNMT expression.

---

## 3. Key genes and interaction modules

### 3.1. TREM2
- **Direction:** Up, log2FC +4.91.
- **Role:** Central marker of the disease-associated macrophage program; likely involved in lipid sensing and macrophage survival/activation.
- **Gene-gene relationships:** TREM2 is co-expressed with FABP5 and CAPG in lipid-associated macrophages; this is a co-expression / cell-state relationship. TREM2 signals through DAP12/TYROBP, but those genes are not in the input table, and no direct physical interaction with FABP5 or CAPG should be inferred from these data.

### 3.2. Resident Kupffer cell module
- **Genes:** TIMD4, LYVE1, MRC1, CD163, MARCO, CD5L, FOLR2, CSF1R, CD209, SIGLEC1, SPIC, CR1, P2RY13, MS4A6E
- **Direction:** All down.
- **Role:** Defines the homeostatic liver-resident macrophage and sinusoidal-associated cell compartment whose markers are lost in MASH.
- **Gene-gene relationships:** These are co-expressed lineage markers and pathway co-members in phagocytosis/scavenger functions; they are not direct physical interaction partners.

### 3.3. FABP5 / CAPG module
- **Direction:** FABP5 log2FC +2.85; CAPG log2FC +2.57.
- **Role:** Lipid handling and actin regulation in disease-associated macrophages; supports the TREM2-positive cellular program.
- **Gene-gene relationships:** Co-expression and functional co-membership in lipid-associated macrophages, not direct physical interaction.

### 3.4. CXCL10
- **Direction:** Up, log2FC +3.46.
- **Role:** Interferon-responsive chemokine; drives recruitment of CXCR3-positive immune cells.
- **Gene-gene relationships:** CXCL10 is downstream of IFN/NF-κB signaling and therefore pathway-related to UBD and TNFRSF12A, but no direct physical interaction is supported by current data.

### 3.5. UBD
- **Direction:** Up, log2FC +4.15.
- **Role:** Interferon-inducible ubiquitin-like protein; may promote NF-κB activation and proteotoxic stress responses.
- **Gene-gene relationships:** Regulatory/pathway relationship with inflammatory signaling; not direct physical interaction with CXCL10 or TNFRSF12A.

### 3.6. TNFRSF12A
- **Direction:** Up, log2FC +3.27.
- **Role:** TWEAK receptor; can activate NF-κB and contribute to liver inflammation and regeneration.
- **Gene-gene relationships:** Pathway co-membership with CXCL10 and UBD in NF-κB/interferon-related inflammatory signaling.

### 3.7. FOXM1 / EME1 / TP53I3 / CYCS module
- **Direction:** All up (FOXM1 +2.14, EME1 +1.88, TP53I3 +3.26, CYCS +1.56).
- **Role:** Cell-cycle progression, DNA-damage response, p53 stress signaling and intrinsic apoptosis.
- **Gene-gene relationships:** Pathway co-membership in cell-cycle and DNA-damage/apoptosis networks; not necessarily direct physical interactions.

### 3.8. CBS / GNMT / MTHFD1L / GGTLC1 module
- **Direction:** CBS down (−1.25), CNPY3-GNMT down (−1.76), SCLY down (−1.28), MTHFD1L up (+1.72), GGTLC1 up (+2.33).
- **Role:** Altered sulfur amino-acid metabolism, methylation status, glutathione turnover and one-carbon metabolism.
- **Gene-gene relationships:** Enzymatic pathway co-membership through shared metabolites; no direct physical interaction implied.

### 3.9. MANF / mitochondrial stress module
- **Direction:** MANF up (+1.85), TIMM17A up (+1.28), CYCS up (+1.56), mitochondrial tRNAs up.
- **Role:** ER stress survival and mitochondrial/translational stress.
- **Gene-gene relationships:** These genes are part of a broader cellular stress response but are located in different organelles and are not direct physical partners.

---

## 4. Validation priorities

### 4.1. Single-cell / spatial validation of the Kupffer-to-TREM2-positive macrophage shift
- **Classification:** Confounding or composition check.
- **Why prioritized:** Many of the most significant DE genes are cell-lineage markers. Bulk tissue cannot distinguish changes in cell proportions from changes in gene expression within the same cells.
- **Current evidence:** Reciprocal downregulation of TIMD4/LYVE1/MRC1/CD163/CD5L/FOLR2 and upregulation of TREM2/FABP5/CAPG.
- **External evidence:** Published scRNA-seq studies of human and mouse NASH consistently identify TREM2-positive scar/lipid-associated macrophages and reduced homeostatic Kupffer cell markers.
- **Next step:** Single-cell or single-nucleus RNA-seq, spatial transcriptomics, flow cytometry, or multiplex immunostaining for TREM2 and TIMD4/LYVE1.
- **Status:** Supported hypothesis for a cell-composition shift; mechanistic role remains to be established.

### 4.2. Functional role of TREM2 / FABP5-positive macrophages in MASH progression
- **Classification:** Mechanistic hypothesis.
- **Why prioritized:** The TREM2-positive macrophage program is the most prominent and disease-relevant signal in this dataset.
- **Current evidence:** TREM2, FABP5 and CAPG are upregulated, while resident Kupffer genes are downregulated.
- **External evidence:** TREM2-positive macrophages are reproducibly enriched in fibrotic NASH, but the functional direction — protective versus pathogenic — is still debated and may depend on disease stage and model.
- **Next step:** Macrophage-specific TREM2 ablation or blocking antibodies in diet-induced MASH models; FABP5 perturbation in myeloid cells.
- **Status:** Supported hypothesis for association; causal mechanistic conclusion remains exploratory.

### 4.3. Interferon / CXCL10 / UBD inflammatory axis as a therapeutic target
- **Classification:** Therapeutic target.
- **Why prioritized:** This pathway is druggable and may amplify immune injury in MASH.
- **Current evidence:** CXCL10, UBD and TNFRSF12A are all upregulated.
- **External evidence:** CXCL10 is elevated in NAFLD/NASH and promotes T-cell/monocyte recruitment; UBD/FAT10 is linked to inflammation and NF-κB activation. However, existing drug candidates do not by themselves prove efficacy in MASH.
- **Next step:** Neutralization of CXCL10 or IFNγ, or knockdown of UBD, in diet-induced MASH models; measure inflammation, macrophage infiltration and fibrosis.
- **Status:** Supported hypothesis, not established therapeutic evidence.

### 4.4. One-carbon / sulfur / glutathione metabolic shift
- **Classification:** Mechanistic hypothesis.
- **Why prioritized:** The coordinated changes in CBS, GNMT, MTHFD1L, SCLY and GGTLC1 point to a potentially targetable metabolic vulnerability.
- **Current evidence:** CBS and GNMT-related transcript down; MTHFD1L and GGTLC1 up.
- **External evidence:** CBS deficiency and low hydrogen sulfide are associated with hepatic steatosis/injury; GNMT knockout mice develop steatosis and liver cancer. Human MASH metabolomic confirmation is still incomplete.
- **Next step:** Targeted metabolomics for SAM/SAH, glutathione, homocysteine, cystathionine and hydrogen sulfide; stable-isotope flux studies; dietary interventions.
- **Status:** Exploratory hypothesis.

### 4.5. Hepatocyte DNA-damage / cell-cycle response as a MASH-to-HCC risk module
- **Classification:** Mechanistic hypothesis.
- **Why prioritized:** MASH increases hepatocellular carcinoma risk; FOXM1, EME1, TP53I3 and CYCS may reflect DNA damage and proliferative pressure.
- **Current evidence:** FOXM1, EME1, TP53I3 and CYCS are all upregulated.
- **External evidence:** FOXM1 is involved in liver regeneration and hepatocellular carcinoma; DNA damage markers are elevated in MASH.
- **Next step:** Quantify γH2AX, Ki67, p53 activation and DNA-repair activity in MASH liver tissue; test FOXM1 inhibition in preclinical MASH/HCC models.
- **Status:** Supported hypothesis for the presence of a stress/proliferation program; causal relationship to tumor progression is exploratory.

---

## 5. Evidence grounding

The interpretation relies on several evidence types:

- **Direct dataset evidence:** FDR-significant differential expression directions for the listed genes.
- **Pathway / ontology evidence:** Functional annotations such as Hallmark Interferon Gamma Response, KEGG Cysteine and Methionine Metabolism, and Reactome Homologous Recombination Repair.
- **Disease-association evidence:** Prior human and mouse studies identifying TREM2-positive macrophages in MASH and loss of Kupffer cell identity.
- **Expression / tissue-specific evidence:** Genes such as TIMD4, LYVE1, MRC1, CD163, CD5L and FOLR2 are established tissue-resident macrophage markers; FOXM1 and EME1 are established cell-cycle/DNA-repair genes.
- **Genetic / clinical evidence:** Mouse models linking GNMT and CBS perturbation to steatosis/liver disease.
- **Protein interaction / regulatory evidence:** Known signaling biology such as TREM2-DAP12, TNFRSF12A-NF-κB, and UBD/FAT10-mediated NF-κB regulation.

These evidence sources are not fully independent. The bulk transcriptomic data and published scRNA-seq data likely reflect the same underlying biology, namely a shift in hepatic macrophage populations. Marker-gene identities, however, were established independently from the current dataset. Pathway annotations are curated and can support biological interpretation, but they do not by themselves prove that a pathway is active in the sampled tissue.

---

## 6. Limitations and alternative explanations

### 6.1. Bulk tissue cell-composition effects
Many significant genes are lineage markers. The apparent loss of Kupffer cell genes and gain of TREM2-positive macrophage genes may reflect changes in cell proportions rather than transcriptional regulation within a stable cell population. This is the single most important limitation.

**How to address:** scRNA-seq, spatial transcriptomics, flow cytometry, or computational deconvolution with liver reference profiles.

### 6.2. Unknown clinical and disease-stage heterogeneity
MASH severity, fibrosis stage, age, sex, BMI, diabetes status, medication exposure and alcohol history are not provided. These factors strongly influence the transcriptome and could explain why some expected signals, such as VCAM1 and P4HA1 upregulation, are absent or reversed.

**How to address:** Stratify by fibrosis stage and metabolic comorbidities; collect patient-level metadata; use animal models with defined diets and timepoints.

### 6.3. Non-coding, mitochondrial tRNA and pseudogene signals
Several top DE features are mitochondrial tRNAs, pseudogenes, antisense transcripts or lncRNAs. These may be biologically meaningful, but they can also reflect technical artifacts related to RNA quality, mitochondrial DNA contamination, or alignment ambiguity. The mitochondrial/translational program in particular should be verified with orthogonal assays.

**How to address:** Confirm by qPCR with cDNA vs gDNA controls; measure mitochondrial DNA copy number; compare nuclear-encoded mitochondrial genes; use RNA-seq alignments against mitochondrial reference with quality filters.

### 6.4. Gene-level differential expression is not pathway-level evidence
No formal gene-set enrichment analysis was performed on the full ranked gene list. The programs described here are based on selected significant genes and curated pathway knowledge, which can overstate biological coherence.

**How to address:** Run GSEA or ORA using the full ranked statistics with Hallmark/GO/Reactome/KEGG gene sets.

### 6.5. Association-versus-causation ambiguity
All conclusions are based on transcript abundance at a single timepoint. Upregulation of TREM2, FOXM1, UBD or MTHFD1L does not prove that these genes drive MASH; they may reflect compensatory, protective or bystander responses.

**How to address:** Functional perturbation studies in vivo and in vitro, ideally with temporal resolution and cell-type specificity, before assigning causal roles.

---

## Summary statement

The current transcriptomic results most convincingly support a model of MASH as a disease of hepatic immune cell remodeling, with loss of homeostatic Kupffer cell markers, emergence of TREM2-positive disease-associated macrophages, and activation of interferon/NF-κB inflammatory signaling. Superimposed on this are hepatocyte injury, mitochondrial/ER stress, and altered one-carbon/sulfur/glutathione metabolism. The strongest, most reproducible interpretation is the myeloid identity shift; the metabolic and cell-cycle programs are biologically plausible but require functional, metabolomic and single-cell validation.
